Contract Research & Services
Contract Services

Contract Services

Mylan to buy global marketing rights of Mapi’s Glatiramer acetate product Mylan has agreed to acquire global marketing rights of Israel-based Mapi Pharma’s GA Depot, a long-acting once-monthly Glatiramer acetate product.
Contract Research & Services > Contract Services > News
Ionis licenses to Akcea global rights to inotersen in $1.7bn deal By PBR Staff Writer
Ionis Pharmaceuticals has licensed to Akcea Therapeutics worldwide rights to inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx, in a transaction potentially worth about $1.7bn.
Contract Research & Services > Contract Services > News Valeant, Kaken sign license deal to develop new chemical entity for psoriasis Valeant Pharmaceuticals International's subsidiary and Kaken Pharmaceutical have entered into a license agreement to develop and commercialize products featuring KP-470, an investigational compound for the topical treatment of psoriasis.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Data Integrity A Closer Look
| By NSF International
Data integrity remains a perennial hot topic impacting the pharma biotech industry and the trend has been picking up steam; the number of data integrity-related warning letters has increased consistently since 2010. A number of new guidance documents came out in 2016 by FDA, MHRA, EMA PIC/S and the WHO and yet companies continue to grapple with data integrity issues.
Contract Research & Services > Contract Services > White Papers
Preparing For A Regulatory Inspection
Learn how we helped a company prepare for a regulatory inspection. The key message that came from the project was that you need to approach inspection preparation in an open and collaborative manner. Sites will have the answers to the questions if the right people are asked.
Contract Research & Services > Contract Services > Case Studies
Hierarchy For Capa Effectiveness
| By NSF International
Have you ever reviewed an investigation report and wondered whether the proposed corrective and preventive action (CAPA) would be effective? Sometimes, we shrug our shoulders and say, “At least they put something in place”. We all know that the FDA expects us to include an effectiveness check, but do we have enough guidance to make these checks meaningful? NSF suggests that you consider these three questions: 1. What will you measure? 2. When will you measure it? 3. What is your acceptance standard?
Contract Research & Services > Contract Services > White Papers
Upcoming Pharmaceutical Courses from NSF
Make sure you remember to take advantage of any discounts you could be entitled to! Get in touch if you're interested in bringing any of this training on-site.
Contract Research & Services > Contract Services > Press Releases
Managing your weight never tasted so good! New weight loss gummies,Visit us at booth E24 at Vitafoods 2018.
Nutrition is a trending topic for consumers today, but taste, convenience, and ease of use are also influencing purchasing decisions. With such demands from discerning consumers increase, and summer just around the corner, everybody is focused on getting their body in the best possible shape.
Contract Research & Services > Contract Services > Press Releases
NSF International Launches Pharma Biotech eLearning
NSF International provides a comprehensive range of support services for the pharmaceutical industry covering consulting, training, auditing, remediation, quality systems and regulatory guidance on a global basis.
Contract Research & Services > Contract Services > Press Releases
Mylan to buy global marketing rights of Mapi’s Glatiramer acetate product
Mylan has agreed to acquire global marketing rights of Israel-based Mapi Pharma’s GA Depot, a long-acting once-monthly Glatiramer acetate product.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests